Gastric Cancer

, Volume 11, Issue 1, pp 37–46 | Cite as

Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: clinicopathological significance

  • Naruo Tokuyasu
  • Kohei Shomori
  • Keisuke Nishihara
  • Hiroki Kawaguchi
  • Shinji Fujioka
  • Kensaku Yamaga
  • Masahide Ikeguchi
  • Hisao Ito
Original Article



The origin licensing factor minichromosome maintenance 2 (MCM2) has recently been identified as a critical regulator of proliferation in both normal and neoplastic cells. This study examined whether MCM2 expression was of prognostic relevance in patients with stage III gastric carcinoma and whether the expression of this marker showed any correlation with clinicopathological characteristics. In addition, we evaluated whether the expression of this proliferation marker was correlated with that of another marker, Ki-67, in gastric carcinoma.


We examined the immunohistochemical expression of MCM2, Ki-67, and p53 in 103 surgically removed stage III gastric carcinomas, which consisted of 60 intestinal-type and 43 diffuse-type carcinomas. The labeling indices (LIs) of MCM2 and Ki-67 in cancer cells were compared with clinicopathological characteristics, p53 expression, and overall survival rates.


The mean MCM2 and Ki-67 LIs were 69.1 ± 11.8% and 48.2 ± 14.5%, respectively, in the intestinal carcinomas, and 43.7 ± 9.9% and 24.9 ± 11.0%, respectively, in the diffuse carcinomas. The LIs of these proteins revealed no significant association with clinicopathological characteristics or with p53 expression in the carcinomas. Kaplan-Meier survival curves showed that, in the patients with diffuse carcinoma, those with higher MCM2 LIs had a poorer prognosis (P < 0.05), but the MCM2 LI was not correlated with prognosis for those with intestinal carcinoma (P = 0.25). Ki-67 expression had no significant correlation with prognosis in either intestinal-type or diffuse-type carcinomas. Multivariate Cox regression analysis confirmed that MCM2 was an independent prognostic factor in patients with diffuse carcinoma.


Our data suggest that MCM2 is a useful prognostic marker in patients stage III diffuse-type gastric carcinoma.

Key words

Minichromosome maintenance protein 2 (MCM2) Gastric carcinoma Ki-67 p53 Prognostic value 


  1. 1.
    Parkin DM, Pisani P, Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999;80:827–841.PubMedCrossRefGoogle Scholar
  2. 2.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 2006;24:4991–4997.PubMedCrossRefGoogle Scholar
  4. 4.
    Dimitrova DS, Prokhorova TA, Blow JJ, Todorov IT, Gilbert DM. Mammalian nuclei become licensed for DNA replication during late telophase. J Cell Sci 2002;115:51–59.PubMedCrossRefGoogle Scholar
  5. 5.
    Blow JJ, Hodgson B. Replication licensing-defining the proliferative state? Trends Cell Biol 2002;12:72–78.PubMedCrossRefGoogle Scholar
  6. 6.
    Mendez J, Stillman B. Chromatin association of human origin recognition complex, cdc6, and minichromosome maintenance proteins during the cell cycle: assembly of prereplication complexes in late mitosis. Mol Cell Biol 2000;20:8602–8612.PubMedCrossRefGoogle Scholar
  7. 7.
    Takeda DY, Dutta A. DNA replication and progression through S phase. Oncogene 2005;24:2827–2843.PubMedCrossRefGoogle Scholar
  8. 8.
    Eward KL, Obermann EC, Shreeram S, Loddo M, Fanshawe T, Williams C, et al. DNA replication licensing in somatic and germ cells. J Cell Sci 2004;117:5875–5886.PubMedCrossRefGoogle Scholar
  9. 9.
    Stoeber K, Tlsty T, Happerfield L, Thomas G, Romanov S, Bobrow L. DNA replication licensing and human cell proliferation. J Cell Sci 2001;114:2027–2041.PubMedGoogle Scholar
  10. 10.
    Kodani I, Shomori K, Osaki M, Kuratate I, Ryoke K, Ito H: Expression of minichromosome maintenance 2 (MCM2), Ki-67, and cell-cycle-related molecules, and apoptosis in the normaldysplasia-carcinoma sequence of the oral mucosa. Pathobiology 2001;69:150–158.PubMedCrossRefGoogle Scholar
  11. 11.
    Hashimoto K, Araki K, Osaki M, Nakamura H, Tomita K, Shimizu E, et al. MCM2 and Ki-67 expression in human lung adenocarcinoma: prognostic implications. Pathobiology 2004;71:193–200.PubMedCrossRefGoogle Scholar
  12. 12.
    Osaki M, Osaki M, Yamashita H, Shomori K, Yoshida H, Ito H. Expression of minichromosome maintenance-2 in human malignant fibrous histiocytomas: correlations with Ki-67 and p53 expression, and apoptosis. Int J Mol Med 2002;10:161–168.PubMedGoogle Scholar
  13. 13.
    Freeman A, Morris LS, Mills AD, Stoeber K, Askey RA, Williams GH, et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999;5:2121–2132.PubMedGoogle Scholar
  14. 14.
    Todorov IT, Werness BA, Wang HQ, Buddharaju LN, Todorova PD, Slocum HK, et al. HsMCM2/BM28:a novel proliferation marker for human tumors and normal tissues. Lab Invest 1998;78:73–78.PubMedGoogle Scholar
  15. 15.
    Japanese Gastric Cancer Association Registration Committee. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer 2006;9:51–66.CrossRefGoogle Scholar
  16. 16.
    Lauren P. The two histological main types of gastric cancer: diffuse and so-called intestinal type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31–49.PubMedGoogle Scholar
  17. 17.
    Japanese Research Society for Gastric Cancer. Japanese classification of gastric carcinoma. Tokyo: Kanehara; 1995.Google Scholar
  18. 18.
    Kato H, Miyazaki T, Fukai Y, Nakajima M, Sohda M, Takita J, Masuda N, et al. A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma. J Surg Oncol 2003;84:24–30.PubMedCrossRefGoogle Scholar
  19. 19.
    Gonzalez MA, Pinder SE, Callagy G, Vowler SL, Morris LS, Bird K, et al. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol 2003;21:4306–4313.PubMedCrossRefGoogle Scholar
  20. 20.
    Hunt DP, Freeman A, Morris LS, Burnet NG, Bird K, Davies TW, et al. Early recurrence of benign meningioma correlates with expression of mini-chromosome maintenance-2 protein. Br J Neurosurg 2002;16:10–15.PubMedCrossRefGoogle Scholar
  21. 21.
    Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH. Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki-67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol 2001;27:305–313.PubMedCrossRefGoogle Scholar
  22. 22.
    Meng MV, Grossfeld GD, Williams GH, Dilworth S, Stoeber K, Mulley TW, et al. Minichromosome maintenance protein 2 expression in prostate: characterization and association with outcome after therapy for cancer. Clin Cancer Res 2001;7:2712–2718.PubMedGoogle Scholar
  23. 23.
    Rodins K, Cheale M, Coleman N, Fox SB. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility. Clin Cancer Res 2002;8:1075–1081.PubMedGoogle Scholar
  24. 24.
    Kruger S, Thorns C, Stocker W, Muller-Kunert E, Bohle A, Feller AC. Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder. Eur Urol 2003;43:138–145.PubMedCrossRefGoogle Scholar
  25. 25.
    Chatrath P, Scott IS, Morris LS, Davies RJ, Rushbrook SM, Bird K, et al. Aberrant expression of minichromosome maintenance protein-2 and Ki-67 in laryngeal squamous epithelial lesions. Br J Cancer 2003;89:1048–1054.PubMedCrossRefGoogle Scholar
  26. 26.
    Scholzen T, Gerdes J. The Ki67 protein: from the known and the unknown. J Cell Physiol 2000;182:311–322.PubMedCrossRefGoogle Scholar
  27. 27.
    Brown DC, Gatter KC. Monoclonal antibody Ki-67:its use in histopathology. Histopathology 1990;17:489–503.PubMedCrossRefGoogle Scholar
  28. 28.
    Verheijen R, Kuijpers HJ, Schlingemann RO, Boehmer AL, van Driel R, Brakenhoff GJ, et al. Ki-67 detects a nuclear matrix-associated proliferation-related antigen: I. Intracellular localization during interphase. J Cell Sci 1989;92:123–130.PubMedGoogle Scholar
  29. 29.
    Verheijen R, Kuijpers HJ, van Driel R, Beck JL, van Dierendonck JH, Brakenhoff GJ, et al. Ki-67 detects a nuclear matrix-associated proliferation-related antigen. II. Localization in mitotic cells and association with chromosomes. J Cell Sci 1989;92:531–540.PubMedGoogle Scholar
  30. 30.
    Baisch H, Gerdes J. Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet 1987;20:387–391.PubMedGoogle Scholar
  31. 31.
    Müller W, Schneiders A, Meier S, Hommel G, Gabbert HE. Immunohistochemical study on the prognostic value of MIB-1 in gastric carcinoma. Br J Cancer 1996;74:759–765.PubMedGoogle Scholar
  32. 32.
    Ikeda M, Shomori K, Endo K, Makino T, Matssura T, Ito H. Frequent occurrence of apoptosis is an early event in the oncogenesis of human gastric carcinoma. Virchows Arch 1998;43:43–47.CrossRefGoogle Scholar
  33. 33.
    Inada T, Imura J, Ichikawa A, Ogata Y, Shimamura K. Proliferative activity of gastric cancer assessed by immunostaining for proliferating cell nuclear antigen. J Surg Oncol 1993;54:146–152.PubMedCrossRefGoogle Scholar
  34. 34.
    Zheng H, Takahashi H, Murai Y, Cui Z, Nomoto K, Miwa S, et al. Pathobiological characteristics of intestinal and diffuse-type gastric carcinoma in Japan: an immunostaining study on the tissue microarray. J Clin Pathol 2007;60:273–277.PubMedCrossRefGoogle Scholar
  35. 35.
    Hippo Y, Taniguchi H, Tsusumi S, Machida N, Chong JM, Fukayama M, et al. Global gene expression analysis of gastric cancer by oligonucleotide microarrays. Cancer Res 2002;62:233–240.PubMedGoogle Scholar
  36. 36.
    Llanos O, Butte JM, Crovari F, Duarte I, Guzman S. Survival of young patients after gastrectomy for gastric cancer. World J Surg 2006;30:17–20.PubMedCrossRefGoogle Scholar
  37. 37.
    Kim DY, Joo JK, Ryu SY, Park YK, Kim YJ, Kim SK. Clinocopathologic characteristics of gastric carcinoma in elderly patients: a comparison with young patients. World J Gastroenterol 2005;11:22–26.PubMedGoogle Scholar
  38. 38.
    Whitfield ML, Sherlock G, Saldanha AJ, Murray JI, Ball CA, Alexander KE, et al. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Mol Biol Cell 2002;13:1977–2000.PubMedCrossRefGoogle Scholar
  39. 39.
    Ikeguchi M, Saito H, Kondo A, Tsujitani S, Maeta M, Kaibara N. Mutated p53 protein expression and proliferative activity in advanced gastric cancer. Hepatogastroenterology 1999;46:2648–2653.PubMedGoogle Scholar

Copyright information

© The International Gastric Cancer Association and The Japanese Gastric Cancer Association 2008

Authors and Affiliations

  • Naruo Tokuyasu
    • 1
  • Kohei Shomori
    • 1
  • Keisuke Nishihara
    • 1
  • Hiroki Kawaguchi
    • 3
  • Shinji Fujioka
    • 1
  • Kensaku Yamaga
    • 1
  • Masahide Ikeguchi
    • 2
  • Hisao Ito
    • 1
  1. 1.Division of Organ Pathology, Department of Microbiology and Pathology, Faculty of MedicineTottori UniversityTottoriJapan
  2. 2.Division of Surgical Oncology, Department of Surgery, Faculty of MedicineTottori UniversityTottoriJapan
  3. 3.Division of SurgeryYonago Medical Center HospitalTottoriJapan

Personalised recommendations